(FNF) Fidelity National Financial - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US31620R3030
Stock:
Total Rating 24
Risk 66
Buy Signal 0.09
| Risk 5d forecast | |
|---|---|
| Volatility | 26.5% |
| Relative Tail Risk | 1.15% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.37 |
| Alpha | -20.29 |
| Character TTM | |
|---|---|
| Beta | 0.574 |
| Beta Downside | 0.537 |
| Drawdowns 3y | |
|---|---|
| Max DD | 22.50% |
| CAGR/Max DD | 0.72 |
EPS (Earnings per Share)
Revenue
Description: FNF Fidelity National Financial
Fidelity National Financial, Inc., together with its subsidiaries, provides various insurance products in the United States. The company operates through Title, F&G, and Corporate and Other segments. It offers title insurance, escrow, and other title related services, including trust activities, trustee sales guarantees, recordings and reconveyances, and home warranty products. The company also provides technology and transaction services to the real estate and mortgage industries; and mortgage transaction services, including title-related services and facilitation of production and management of mortgage loans. In addition, it offers annuity and life insurance products, such as deferred and immediate annuities, as well as indexed universal life insurance products; and funding agreements and pension risk transfer (PRT) solutions. Further, the company engages in the real estate brokerage business. Fidelity National Financial, Inc. was incorporated in 2005 and is headquartered in Jacksonville, Florida.
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income: 602.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -2.59 > 1.0 |
| NWC/Revenue: 524.6% < 20% (prev 342.3%; Δ 182.3% < -1%) |
| CFO/TA 0.05 > 3% & CFO 5.82b > Net Income 602.0m |
| Net Debt (-71.43b) to EBITDA (2.26b): -31.59 < 3 |
| Current Ratio: 1613 > 1.5 & < 3 |
| Outstanding Shares: last quarter (270.0m) vs 12m ago -1.10% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 14.14% > 50% (prev 14.00%; Δ 0.13% > 0%) |
| Interest Coverage Ratio: 4.66 > 6 (EBITDA TTM 2.26b / Interest Expense TTM 242.0m) |
Altman Z'' 4.81
| A: 0.70 (Total Current Assets 75.83b - Total Current Liabilities 47.0m) / Total Assets 109.01b |
| B: 0.06 (Retained Earnings 6.29b / Total Assets 109.01b) |
| C: 0.01 (EBIT TTM 1.13b / Avg Total Assets 102.19b) |
| D: -0.02 (Book Value of Equity -1.68b / Total Liabilities 100.04b) |
| Altman-Z'' Score: 4.81 = AA |
Beneish M
| DSRI: none (Receivables none/13.85b, Revenue 14.45b/13.35b) |
| GMI: 0.62 (GM 98.19% / 60.98%) |
| AQI: none (AQ_t none / AQ_t-1 none) |
| SGI: 1.08 (Revenue 14.45b / 13.35b) |
| TATA: -0.05 (NI 602.0m - CFO 5.82b) / TA 109.01b) |
| Beneish M-Score: cannot calculate (missing components) |
What is the price of FNF shares?
As of February 27, 2026, the stock is trading at USD 52.20 with a total of 2,196,082 shares traded.
Over the past week, the price has changed by -3.71%, over one month by -4.74%, over three months by -8.30% and over the past year by -9.44%.
Over the past week, the price has changed by -3.71%, over one month by -4.74%, over three months by -8.30% and over the past year by -9.44%.
Is FNF a buy, sell or hold?
Fidelity National Financial has received a consensus analysts rating of 4.25.
Therefore, it is recommended to buy FNF.
- StrongBuy: 2
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the FNF price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 68.4 | 31% |
| Analysts Target Price | 68.4 | 31% |
FNF Fundamental Data Overview February 24, 2026
P/E Trailing = 23.5882
P/E Forward = 12.8205
P/S = 0.9792
P/B = 2.0487
P/EG = 10.83
Revenue TTM = 14.45b USD
EBIT TTM = 1.13b USD
EBITDA TTM = 2.26b USD
Long Term Debt = 4.40b USD (from longTermDebt, two quarters ago)
Short Term Debt = unknown (none)
Debt = 4.40b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -71.43b USD (from netDebt column, last quarter)
Enterprise Value = -57.29b USD (14.14b + Debt 4.40b - CCE 75.83b)
Interest Coverage Ratio = 4.66 (Ebit TTM 1.13b / Interest Expense TTM 242.0m)
EV/FCF = -10.10x (Enterprise Value -57.29b / FCF TTM 5.67b)
FCF Yield = -9.90% (FCF TTM 5.67b / Enterprise Value -57.29b)
FCF Margin = 39.28% (FCF TTM 5.67b / Revenue TTM 14.45b)
Net Margin = 4.17% (Net Income TTM 602.0m / Revenue TTM 14.45b)
Gross Margin = unknown ((Revenue TTM 14.45b - Cost of Revenue TTM 262.0m) / Revenue TTM)
Tobins Q-Ratio = -0.53 (set to none) (Enterprise Value -57.29b / Total Assets 109.01b)
Interest Expense / Debt = 1.39% (Interest Expense 61.0m / Debt 4.40b)
Taxrate = 21.0% (US default 21%)
NOPAT = 890.3m (EBIT 1.13b * (1 - 21.00%))
Current Ratio = 1613 (out of range, set to none) (Total Current Assets 75.83b / Total Current Liabilities 47.0m)
Debt / Equity = 0.49 (Debt 4.40b / totalStockholderEquity, last quarter 8.97b)
Debt / EBITDA = -31.59 (Net Debt -71.43b / EBITDA 2.26b)
Debt / FCF = -12.59 (Net Debt -71.43b / FCF TTM 5.67b)
Total Stockholder Equity = 8.28b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.59% (Net Income 602.0m / Total Assets 109.01b)
RoE = 7.27% (Net Income TTM 602.0m / Total Stockholder Equity 8.28b)
RoCE = 8.89% (EBIT 1.13b / Capital Employed (Equity 8.28b + L.T.Debt 4.40b))
RoIC = 7.15% (NOPAT 890.3m / Invested Capital 12.45b)
WACC = 6.38% (E(14.14b)/V(18.54b) * Re(8.03%) + D(4.40b)/V(18.54b) * Rd(1.39%) * (1-Tc(0.21)))
Discount Rate = 8.03% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.18%
[DCF] Terminal Value 85.80% ; FCFF base≈6.38b ; Y1≈7.35b ; Y5≈10.32b
[DCF] Fair Price = 1224 (EV 260.71b - Net Debt -71.43b = Equity 332.14b / Shares 271.3m; r=6.38% [WACC]; 5y FCF grow 17.82% → 2.90% )
EPS Correlation: 6.53 | EPS CAGR: 0.77% | SUE: -0.19 | # QB: 0
Revenue Correlation: 67.22 | Revenue CAGR: 9.26% | SUE: 0.93 | # QB: 2
EPS next Quarter (2026-03-31): EPS=1.19 | Chg7d=-0.017 | Chg30d=-0.039 | Revisions Net=-1 | Analysts=5
EPS current Year (2026-12-31): EPS=6.13 | Chg7d=-0.047 | Chg30d=-0.057 | Revisions Net=+0 | Growth EPS=+23.4% | Growth Revenue=+7.1%
EPS next Year (2027-12-31): EPS=7.02 | Chg7d=-0.140 | Chg30d=-0.100 | Revisions Net=+1 | Growth EPS=+14.4% | Growth Revenue=+7.6%
[Analyst] Revisions Ratio: -0.33 (1 Up / 2 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.8% (Discount Rate 8.0% - Earnings Yield 4.2%)
[Growth] Growth Spread = +24.0% (Analyst 27.8% - Implied 3.8%)
P/E Forward = 12.8205
P/S = 0.9792
P/B = 2.0487
P/EG = 10.83
Revenue TTM = 14.45b USD
EBIT TTM = 1.13b USD
EBITDA TTM = 2.26b USD
Long Term Debt = 4.40b USD (from longTermDebt, two quarters ago)
Short Term Debt = unknown (none)
Debt = 4.40b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -71.43b USD (from netDebt column, last quarter)
Enterprise Value = -57.29b USD (14.14b + Debt 4.40b - CCE 75.83b)
Interest Coverage Ratio = 4.66 (Ebit TTM 1.13b / Interest Expense TTM 242.0m)
EV/FCF = -10.10x (Enterprise Value -57.29b / FCF TTM 5.67b)
FCF Yield = -9.90% (FCF TTM 5.67b / Enterprise Value -57.29b)
FCF Margin = 39.28% (FCF TTM 5.67b / Revenue TTM 14.45b)
Net Margin = 4.17% (Net Income TTM 602.0m / Revenue TTM 14.45b)
Gross Margin = unknown ((Revenue TTM 14.45b - Cost of Revenue TTM 262.0m) / Revenue TTM)
Tobins Q-Ratio = -0.53 (set to none) (Enterprise Value -57.29b / Total Assets 109.01b)
Interest Expense / Debt = 1.39% (Interest Expense 61.0m / Debt 4.40b)
Taxrate = 21.0% (US default 21%)
NOPAT = 890.3m (EBIT 1.13b * (1 - 21.00%))
Current Ratio = 1613 (out of range, set to none) (Total Current Assets 75.83b / Total Current Liabilities 47.0m)
Debt / Equity = 0.49 (Debt 4.40b / totalStockholderEquity, last quarter 8.97b)
Debt / EBITDA = -31.59 (Net Debt -71.43b / EBITDA 2.26b)
Debt / FCF = -12.59 (Net Debt -71.43b / FCF TTM 5.67b)
Total Stockholder Equity = 8.28b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.59% (Net Income 602.0m / Total Assets 109.01b)
RoE = 7.27% (Net Income TTM 602.0m / Total Stockholder Equity 8.28b)
RoCE = 8.89% (EBIT 1.13b / Capital Employed (Equity 8.28b + L.T.Debt 4.40b))
RoIC = 7.15% (NOPAT 890.3m / Invested Capital 12.45b)
WACC = 6.38% (E(14.14b)/V(18.54b) * Re(8.03%) + D(4.40b)/V(18.54b) * Rd(1.39%) * (1-Tc(0.21)))
Discount Rate = 8.03% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.18%
[DCF] Terminal Value 85.80% ; FCFF base≈6.38b ; Y1≈7.35b ; Y5≈10.32b
[DCF] Fair Price = 1224 (EV 260.71b - Net Debt -71.43b = Equity 332.14b / Shares 271.3m; r=6.38% [WACC]; 5y FCF grow 17.82% → 2.90% )
EPS Correlation: 6.53 | EPS CAGR: 0.77% | SUE: -0.19 | # QB: 0
Revenue Correlation: 67.22 | Revenue CAGR: 9.26% | SUE: 0.93 | # QB: 2
EPS next Quarter (2026-03-31): EPS=1.19 | Chg7d=-0.017 | Chg30d=-0.039 | Revisions Net=-1 | Analysts=5
EPS current Year (2026-12-31): EPS=6.13 | Chg7d=-0.047 | Chg30d=-0.057 | Revisions Net=+0 | Growth EPS=+23.4% | Growth Revenue=+7.1%
EPS next Year (2027-12-31): EPS=7.02 | Chg7d=-0.140 | Chg30d=-0.100 | Revisions Net=+1 | Growth EPS=+14.4% | Growth Revenue=+7.6%
[Analyst] Revisions Ratio: -0.33 (1 Up / 2 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.8% (Discount Rate 8.0% - Earnings Yield 4.2%)
[Growth] Growth Spread = +24.0% (Analyst 27.8% - Implied 3.8%)